Comparison of Renal Function Biomarkers of Serum Creatinine and Cystatin C in HIV-Infected People on Dolutegravir-Containing Therapy

References

• AIDS and Hepatitis C Professional Group,Society of Infectious Diseases,Chinese Medical Association;Chinese Center for Disease Control and Prevention.The Guidelines for diagnosis and treatment of AIDS in China(version of 2018). Chin J Infect Dis. 2018,36(12):705-724.
   Google Scholar
• Chikwapulo B, Ngwira B, Sagno JB, Evans R. Renal outcomes in patients initiated on tenofovir disoproxil fumarate-based antiretroviral therapy at a community health centre in Malawi. Int J STD AIDS. 2018;29(7):650–657. doi:10.1177/0956462417749733
   Web of Science ®Google Scholar
• Mulenga L, Musonda P, Mwango A, et al. Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia. Clin Infect Dis. 2014;58(10):1473–1480. doi:10.1093/cid/ciu117
   PubMed Web of Science ®Google Scholar
• Kamkuemah M, Kaplan R, Bekker LG, Little F, Myer L. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a primary healthcare setting in South Africa. Trop Med Int Health. 2015;20(4):518–526. doi:10.1111/tmi.12446
   Web of Science ®Google Scholar
• Kinai E, Hanabusa H. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses. 2009;25(4):387–394. doi:10.1089/aid.2008.0202
   Web of Science ®Google Scholar
• Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr. 2004;37(4):1489–1495. doi:10.1097/01.qai.0000138983.45235.02
   PubMed Web of Science ®Google Scholar
• Laprise C, Baril JG, Dufresne S, Trottier H. Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up. Clin Infect Dis. 2013;56(4):567–575. doi:10.1093/cid/cis937
   PubMed Web of Science ®Google Scholar
• Nishijima T, Kawasaki Y, Tanaka N, et al. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up. AIDS. 2014;28(13):1903–1910. doi:10.1097/QAD.0000000000000347
   PubMed Web of Science ®Google Scholar
• Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868):735–743. doi:10.1016/S0140-6736(12)61853-4
   PubMed Web of Science ®Google Scholar
• Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus Abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807–1818. doi:10.1056/NEJMoa1215541
   PubMed Web of Science ®Google Scholar
• Walmsley S, Baumgarten A, Berenguer J, et al. Brief report: dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial. J Acquir Immune Defic Syndr. 2015;70(5):515–519. doi:10.1097/QAI.0000000000000790
   PubMed Web of Science ®Google Scholar
• Stellbrink HJ, Reynes J, Lazzarin A, et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS. 2013;27(11):1771–1778. doi:10.1097/QAD.0b013e3283612419
   PubMed Web of Science ®Google Scholar
• Rapoport A, Husdan H. Endogenous creatinine clearance and serum creatinine in the clinical assessment of kidney function. Can Med Assoc J. 1968;99(4):149–156.
   Web of Science ®Google Scholar
• Longenecker CT, Scherzer R, Bacchetti P, Lewis CE, Grunfeld C, Shlipak MG. HIV viremia and changes in kidney function. AIDS. 2009;23(9):1089–1096. doi:10.1097/QAD.0b013e32832a3f24
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612. doi:10.7326/0003-4819-150-9-200905050-00006
   PubMed Web of Science ®Google Scholar
• Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20–29. doi:10.1056/NEJMoa1114248
   PubMed Web of Science ®Google Scholar
• Suzuki S, Nishijima T, Kawasaki Y, et al. Effect of tenofovir disoproxil fumarate on incidence of chronic kidney disease and rate of estimated glomerular filtration rate decrement in HIV-1-infected treatment-naive asian patients: results from 12-year observational cohort. AIDS Patient Care STDS. 2017;31(3):105–112. doi:10.1089/apc.2016.0286
   PubMed Web of Science ®Google Scholar
• Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381(9):803–815. doi:10.1056/NEJMoa1902824
   PubMed Web of Science ®Google Scholar
• Wijting IE, Rokx C, Zillikens MC, et al. Changes in renal, bone, lipid, and inflammation markers in HIV-1 patients after combination antiretroviral therapy simplification to dolutegravir monotherapy. Int J STD AIDS. 2019;30(11):1042–1048. doi:10.1177/0956462419848962
   Web of Science ®Google Scholar
• Sculier D, Wandeler G, Yerly S, et al. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL’HIV trial. PLoS Med. 2020;17(11):e1003421. doi:10.1371/journal.pmed.1003421
   PubMed Web of Science ®Google Scholar
• Koteff J, Borland J, Chen S, et al. A Phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol. 2013;75(4):990–996. doi:10.1111/j.1365-2125.2012.04440.x
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, DeJesus E, Henry K, et al. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;62(5):483–486. doi:10.1097/QAI.0b013e318286415c
   PubMed Web of Science ®Google Scholar
• Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily Abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010;55(1):49–57. doi:10.1097/QAI.0b013e3181dd911e
   PubMed Web of Science ®Google Scholar
• Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, Phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379(9835):2439–2448. doi:10.1016/S0140-6736(12)60917-9
   PubMed Web of Science ®Google Scholar
• Yukawa S, Watanabe D, Uehira T, Shirasaka T. Clinical benefits of using inulin clearance and cystatin C for determining glomerular filtration rate in HIV-1-infected individuals treated with dolutegravir. J Infect Chemother. 2018;24(3):199–205. doi:10.1016/j.jiac.2017.10.015
   Web of Science ®Google Scholar
• Palich R, Tubiana R, Abdi B, et al. Plasma cystatin C as a marker for estimated glomerular filtration rate assessment in HIV-1-infected patients treated with dolutegravir-based ART. J Antimicrob Chemother. 2018;73(7):1935–1939. doi:10.1093/jac/dky112
   Web of Science ®Google Scholar
• Longenecker CT, Kitch D, Sax PE, et al. Reductions in plasma cystatin C after initiation of antiretroviral therapy are associated with reductions in inflammation: ACTG A5224s. J Acquir Immune Defic Syndr. 2015;69(2):168–177. doi:10.1097/QAI.0000000000000557
   Web of Science ®Google Scholar
• Casado JL, Monsalvo M, Vizcarra P, Fontecha M, Serrano-Villar S, Moreno S. Evaluation of kidney function in HIV-infected patients receiving an antiretroviral regimen containing one or two inhibitors of the tubular secretion of creatinine. HIV Med. 2019;20(10):648–656. doi:10.1111/hiv.12784
   Web of Science ®Google Scholar
• Galizzi N, Galli L, Poli A, Spagnuolo V, Castagna A, Gianotti N. Glomerular filtration rate estimated by cystatin C formulas in HIV-1 patients treated with dolutegravir, rilpivirine or cobicistat. New Microbiol. 2018;41(4):256–261.
   PubMed Web of Science ®Google Scholar
• Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C; California Collaborative Treatment Group, T. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;197(1):102–108. doi:10.1086/524061
   PubMed Web of Science ®Google Scholar
• Mwafongo A, Nkanaunena K, Zheng Y, et al.; AIDS Clinical Trial Group (ACTG) A5208 Team. Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine. AIDS. 2014;28(8):1135–1142. doi:10.1097/QAD.0000000000000202
   Web of Science ®Google Scholar
• Buchacz K, Young B, Baker RK, et al. Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort. J Acquir Immune Defic Syndr. 2006;43(5):626–628. doi:10.1097/01.qai.0000242461.35768.45
   Web of Science ®Google Scholar
• Hailu W, Tesfaye T, Tadesse A. Hyperglycemia after dolutegravir-based antiretroviral therapy. Int Med Case Rep J. 2021;14:503–507. doi:10.2147/IMCRJ.S323233
   Web of Science ®Google Scholar
• McLaughlin M, Walsh S, Galvin S. Dolutegravir-induced hyperglycaemia in a patient living with HIV. J Antimicrob Chemother. 2018;73(1):258–260. doi:10.1093/jac/dkx365
   PubMed Web of Science ®Google Scholar